1. Canadian residents are covered through a tax-funded universal system for a wide range
of health care services. Drugs administered in hospitals are fully covered through the …

Abstract Background: The Common Drug Review (CDR) was created to provide a single
process to review the comparative clinical efficacy and cost effectiveness of new drugs, and …

Objectives Unlike other high-income countries, Canada has no national policy for drugs
treating rare diseases (orphan drugs). Nevertheless, in 2022, the Canadian government …

Background: The CADTH Common Drug Review was established in 2002 to prepare
national health technology assessment reports to guide listing decisions for 18 participating …

Conditional approval of cancer drugs in Canada: accountability and impact on public funding
Page 1 CONDITIONAL APPROVAL OF CANCER DRUGS IN CANADA, Andersen et al. e100 …

With" Big Pharma" garnering an increasing number of negative headlines due to reports of
adverse drug reactions and a surge in prescription drug addiction and overdose deaths …

Objectives This study was conducted to determine whether establishment of the pan-
Canadian Pharmaceutical Alliance (pCPA) was associated with significant changes in drug …

In democratic societies, good governance is the key to assuring the confidence of
stakeholders and other citizens in how governments and organizations interact with and …

Pharmaceutical policy makers are increasingly negotiating reimbursement contracts that
include confidential price terms that may be affected by drug utilization volumes, patterns, or …

Abstract The New Public Governance (NPG) paradigm addresses problems of complex and
fragmented policy‐making. Health care is an increasingly complex policy area, and Canada …